Skip to main content

Table 1 (abstract O3). Subject characteristics

From: Proceedings of the 2018 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Scientific Meeting

 

All, # (%)

50 subjects

CTP A, # (%)

15 subjects

CTP B, # (%)

24 subjects

CTP C, # (%)

11 subjects

P value

Female

35 (70.0)

11 (73.3)

16 (66.7)

8 (72.7)

NS

Caucasian

46 (92.0)

13 (86.7)

23 (95.8)

10 (90.9)

NS

Age of onset

 Median (IQR)

9.62 (6.3, 11.6)

9.30 (6.9, 11.9)

9.27 (4.8, 10.5)

10.3 (5.7, 13.4)

NS

Age at study entry

 Median (IQR)

13 (9.8, 14.5)

13.2 (9.8, 14.1)

11.9 (6.8, 15.2)

13.3 (11.2, 14.3)

NS

Subtype:

    

0.011

 Circumscribed superficial

4 (8.0)

0

1 (4.2)

3 (27.3)

 Circumscribed deep

3 ( 6.0)

0

0

3 (27.3)

 Linear head

12 (24.0)

3 (20.0)

6 (25.0)

3 (27.3)

 Linear trunk/limb

18 (36.0)

8 (53.3)

9 (37.5)

1 (9.1)

 Generalized

5 (10.0)

2 (13.3)

3 (12.5)

0

 Pansclerotic

1 (2.0)

0

1 (4.2)

0

 Mixed

6 (12.0)

2 (13.3)

4 (16.7)

0

Anatomic Location

     

 Head

20 (40.0)

4 (26.7)

11 (45.8)

5 (45.5)

NS

 Trunk

23 (46.0)

7 (46.7)

11 (45.8)

5 (45.5)

NS

 Limb

29 (58.0)

11 (73.3)

15 (62.5)

3 (27.3)

0.052

Prior Systemic

Treatment

9 (18.0)

2 (13.3)

7 (29.2)

0

0.097

ANA positivity

23 (54.8)

5 (41.7)

15 (79.0)

3 (27.3)

0.013

Extracutaneous morbidity

37 (74.0)

11 (73.3)

18 (75.0)

8 (72.7)

NS

Deviation from CTP

24 (48.0)

8 (53.3)

11 (45.8)

5 (45.5)

NS

MD Activity status at 12 months vs baseline

    

NS

 Major improvement

22 (50.0)

4 (33.3)

13 (56.5)

5 (55.5)

 Moderate improvement

15 (34.1)

6 (50.0)

7 (30.4)

2 (22.2)

 Mild improvement

6 (13.6)

2 (16.7)

2 (8.7)

2 (22.2)

 Mild worsening

1 (2.3)

0

1 (4.4)

0

Inadequate response to CTP

13 (26.0)

4 (33.3)

8 (33.3)

1 (9.1)

NS

Any Adverse Event

33 (66.0)

7 (46.7)

17 (70.8)

9 (81.8)

NS

AE grade 1

26 (52.0)

6 (40.0)

11 (45.8)

9 (81.8)

NS

AE grade 2

22 (44.0)

4 (26.7)

14 (58.3)

4 (36.4)

NS

AE Grade 3

1 (2.3)

0

1 (4.4)

0

NS